Novartis AG vs UBS Group AG: Strategic Comparison
Key Differences at a Glance
| Field | Novartis AG | UBS Group AG |
|---|---|---|
| Revenue | $54.5B | $47.7B |
| Founded | 1996 | 1998 |
| Employees | 75,267 | 105,000 |
| Market Cap | $274.1B | $167.8B |
| Headquarters | Switzerland | Switzerland |
Quick Stats Comparison
| Metric | Novartis AG | UBS Group AG |
|---|---|---|
| Revenue | $54.5B | $47.7B |
| Founded | 1996 | 1998 |
| Headquarters | Basel, Switzerland | Zurich and Basel, Switzerland |
| Market Cap | $274.1B | $167.8B |
| Employees | 75,267 | 105,000 |
Novartis AG Revenue vs UBS Group AG Revenue — Year by Year
| Year | Novartis AG | UBS Group AG | Leader |
|---|---|---|---|
| 2025 | $54.5B | $47.7B | Novartis AG |
| 2024 | $50.3B | $42.3B | Novartis AG |
| 2023 | $45.4B | $33.7B | Novartis AG |
Business Model Breakdown
Overview: Novartis AG vs UBS Group AG
This in-depth comparison examines Novartis AG and UBS Group AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novartis AG on its own, evaluating UBS Group AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novartis AG and UBS Group AG is widest.
On the headline numbers, Novartis AG reports annual revenue of $54.5B against $47.7B for UBS Group AG, while their respective market capitalizations stand at $274.1B and $167.8B. Novartis AG is headquartered in Switzerland and UBS Group AG operates from Switzerland, and those different home markets shape how each company competes.
Novartis AG: Novartis AG is a public company listed on NYSE under ticker NVS. Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
UBS Group AG: UBS is less a traditional bank than a global private-wealth platform with a large Swiss banking base and selective investment banking capabilities. The Credit Suisse acquisition increased scale but made execution the central story.
Business Models: How Novartis AG and UBS Group AG Make Money
Novartis AG and UBS Group AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novartis AG and UBS Group AG.
Novartis AG business model: Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.
UBS Group AG business model: UBS makes money from wealth management fees, advisory, lending, Swiss retail and corporate banking, asset management fees, investment banking advisory and capital markets activity, and trading. Wealth management provides the strategic core because asset-based fees recur as long as client assets remain on the platform.
Competitive Advantage: Novartis AG vs UBS Group AG
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novartis AG stack up against those of UBS Group AG.
Novartis AG competitive advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
UBS Group AG competitive advantage: UBS's advantage is the combination of Swiss banking trust, global ultra-high-net-worth coverage, more than USD 7 trillion in invested assets, and the ability to serve clients across wealth management, lending, capital markets, and asset management.
Growth Strategy: Where Novartis AG and UBS Group AG Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Novartis AG and UBS Group AG each plan to expand from here.
Novartis AG growth strategy: Novartis AG's growth strategy centers on this advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.
UBS Group AG growth strategy: UBS is focused on integrating Credit Suisse, reducing duplicate costs, expanding global wealth management relationships, using technology to improve advisor productivity, growing asset management mandates, and keeping the investment bank focused on capital-light advisory and markets strengths.
Financial Picture: Novartis AG vs UBS Group AG
A closer look at the financial trajectory of Novartis AG and UBS Group AG rounds out the comparison.
Novartis AG: Novartis AG reported FY2025 revenue of $54.532B and net income of $13.967B.
UBS Group AG: UBS Group reported USD 7.8 billion in 2025 net profit attributable to shareholders and a CET1 ratio of 14.4%. UBS AG consolidated total revenues were USD 47.7 billion, up from USD 42.3 billion in 2024, as Credit Suisse consolidation and client activity reshaped the revenue base.
Company-Specific SWOT Notes
Novartis AG
After Sandoz and Alcon separations, Novartis is concentrated around branded, higher-margin medicines and specialty platforms.
Large franchises can lose sales quickly when exclusivity ends or payers switch patients to generics and biosimilars.
Radioligand therapy, oncology, immunology, and cardiovascular launches can offset mature-product pressure.
Drug-price controls, reimbursement restrictions, safety findings, and clinical failures can materially affect growth.
UBS Group AG
UBS's advantage is the combination of Swiss banking trust, global ultra-high-net-worth coverage, more than USD 7 trillion in invested assets, and the ability to serve clients across wealth management, lending, capital markets, and asset management.
UBS wins when wealthy clients consolidate advice, custody, lending, markets access, and estate or tax-aware services with one global institution.
The biggest risk is execution failure in the Credit Suisse integration or regulatory capital changes that reduce the economic upside of the merger.
UBS is focused on integrating Credit Suisse, reducing duplicate costs, expanding global wealth management relationships, using technology to improve advisor productivity, growing asset management mandates, and keeping the investment bank focused on capital-light advisory and markets strengths.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Novartis AG | Novartis AG reports the larger revenue base ($54.5B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Novartis AG | Founded in 1996 vs 1998. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Novartis AG | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | UBS Group AG | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Novartis AG | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Novartis AG reports the larger revenue base ($54.5B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1996 vs 1998. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Novartis AG or UBS Group AG?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Novartis AG vs UBS Group AG
Is Novartis AG better than UBS Group AG?
Verdict: Between Novartis AG and UBS Group AG, Novartis AG is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Novartis AG comes out ahead in this Novartis AG vs UBS Group AG comparison.
Who earns more — Novartis AG or UBS Group AG?
Novartis AG earns more with $54.5B in annual revenue versus UBS Group AG's $47.7B. Novartis AG leads on total revenue based on latest verified figures.
Which company has higher revenue — Novartis AG or UBS Group AG?
Novartis AG reported $54.5B, while UBS Group AG reported $47.7B. The revenue leader is Novartis AG based on latest verified figures.
Novartis AG revenue vs UBS Group AG revenue — which is higher?
Novartis AG revenue: $54.5B. UBS Group AG revenue: $47.7B. Novartis AG has the larger revenue base of the two companies.
Sources & References
- Novartis AG Corporate Website
- Novartis AG Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novartis.com
- UBS Group AG Corporate Website
- UBS Group AG Annual Report 2025 - Revenue and Financial Data
- ubs.com
- ubs.com
- ubs.com